GlobeNewswire Inc.··Rosen Law FirmImmutep Stock Plummets 82.6% After Failed Phase III Trial, Sparking Lawsuit
Immutep's $IMMP stock crashed following discontinued Phase III trial for eftilagimod alfa. Rosen Law Firm launches investigation into potential securities claims and class action lawsuit.
IMMPinvestor lossessecurities class action